Company Profiles

driven by the PitchBook Platform

Dragonfly Sciences

Dragonfly Sciences
2005 FOUNDED
OOB STATUS
11-20 EMPLOYEES
Out of Business LATEST DEAL TYPE
Description

Developer of biosimilar products designed to offer complex monoclonal antibodies and soluble receptors. The company's biosimilar products integrates advanced biology tools and precision bioanalytics necessary to develop products to meet the most rigorous regulatory standards for safety and efficacy, providing the biotechnology industry with drugs for treating serious and life threatening disorders ranging from cancer to autoimmune diseases.

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Primary Office
  • 888 Worcester Street
  • Suite 90
  • Wellesley, MA 02482
  • United States

+1 (781) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Dragonfly Sciences’s full profile, request a free trial.

Dragonfly Sciences Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Sep-2015 00.000 Completed Out of Business
2. Convertible Debt 00000 00.000 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Jan-2010 $7.97M $7.97M 0000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Dragonfly Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A1 0,000,000 00.000000 00.00 00 00 00 00 00.000
Series A 0,000,000 00.000000 00.00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

Dragonfly Sciences Executive Team (7)

Name Title Board
Seat
Contact
Info
Frank Lee Ph.D Founder, Board Member & Chief Executive Officer
Elizabeth Moyer Ph.D Head, Nonclinical Development
Michael Gramer Ph.D Head of Process Development and Manufacturing
John Abrams Ph.D Vice President of Antibody Technologies

3 Former Executives

You’re viewing 4 of 7 executives. Get the full list »